新诺威仑卡奈单抗注射液药物临床试验获批

Core Viewpoint - New Horizon (300765) announced that its subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of Lecanemab injection, marking it as the first in China to obtain such approval for this drug [1] Group 1 - The product is a recombinant anti-human beta-amyloid monoclonal antibody drug, classified as a biosimilar to Lecanemab [1] - It is submitted under the category of therapeutic biological products 3.3, aimed at treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [1] - The clinical trial is set to commence shortly following the approval [1]